Italia markets closed
  • Dow Jones

    -19,18 (-0,06%)
  • Nasdaq

    +26,56 (+0,20%)
  • Nikkei 225

    +276,21 (+0,85%)

    -0,0055 (-0,52%)
  • Bitcoin EUR

    -218,00 (-0,87%)
  • CMC Crypto 200

    +4,66 (+0,83%)

    -328,16 (-1,82%)
  • S&P 500

    +7,86 (+0,18%)

Supernus Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 8, 2022

Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc.

ROCKVILLE, Md., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the third quarter of 2022 after the market closes on Tuesday, November 8, 2022.

Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to present the third quarter 2022 financial and business results on Tuesday, November 8, 2022, at 4:30 p.m. ET. Following management’s prepared remarks and discussion of business results, the call will be open for questions.

A live webcast will be accessible in the Events & Presentations section of the Company’s Investor Relations website

Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.

Following the live call, a replay will be available on the Company's website, The webcast will be available on the Company’s website for 60 days following the live call.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.

For more information, please visit


Jack A. Khattar, President and CEO
Tim Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591


Peter Vozzo
ICR Westwicke
Office: (443) 213-0505
Mobile: (443) 377-4767